Trial Profile
Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Malignant-mesothelioma
- Focus Pharmacodynamics
- 05 Dec 2022 Results(n=20) assessing the effect of neoadjuvant durvalumab versus durvalumab plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma published in the Clinical Cancer Research
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 19 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2022.